Theratechnologies

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor

New Data Show Theratechnologies’ SORT1+ Technology is Effective in Many Treatment-Resistant Cancers

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904

Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

MONTREAL, April  16, 2020  (GLOBE NEWSWIRE) -- Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421 stock options, or Options, to purchase an aggregate of 487,421 common shares of Theratechnologies under Nasdaq Listing Rule 5635(c)(4). The grant was made outside of Theratechnologies’ existing share option plan, or Plan, in connection with Mr. Lévesque’s previously-announced employment by Theratechnologies as its President and Chief Executive Officer. The Options were granted as an inducement material to Mr. Lévesque becoming the President and Chief Executive Officer of Theratechnologies on April 6, 2020.

Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Theratechnologies Inc. (THTX) CEO Paul Lévesque on Q1 2020 Results - Earnings Call Transcript

New sub-analysis of MGH Study presented at CROI 2020 New sub-analysis of MGH Study presented at CROI 2020

Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV

Theratechnologies Inc. (THTX) CEO Luc Tanguay on Q4 2019 Results - Earnings Call Transcript

MONTREAL, Feb.  04, 2020  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment  of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in people living with HIV (Study).

Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon

MONTREAL, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today provided preliminary revenue estimates for its recently completed fiscal year 2019 and revenue guidance for fiscal year 2020. 

Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020

News for Theratechnologies Stock (THTX)